169 related articles for article (PubMed ID: 36924180)
1. European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for digestive neuroendocrine carcinoma.
Sorbye H; Grande E; Pavel M; Tesselaar M; Fazio N; Reed NS; Knigge U; Christ E; Ambrosini V; Couvelard A; Tiensuu Janson E
J Neuroendocrinol; 2023 Mar; 35(3):e13249. PubMed ID: 36924180
[TBL] [Abstract][Full Text] [Related]
2. European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for colorectal neuroendocrine tumours.
Rinke A; Ambrosini V; Dromain C; Garcia-Carbonero R; Haji A; Koumarianou A; van Dijkum EN; O'Toole D; Rindi G; Scoazec JY; Ramage J
J Neuroendocrinol; 2023 Jun; 35(6):e13309. PubMed ID: 37345509
[TBL] [Abstract][Full Text] [Related]
3. Neuroendocrine Cancer, Therapeutic Strategies in G3 Cancers.
Rinke A; Gress TM
Digestion; 2017; 95(2):109-114. PubMed ID: 28161703
[TBL] [Abstract][Full Text] [Related]
4. Impact of KRAS and BRAF mutations on treatment efficacy and survival in high-grade gastroenteropancreatic neuroendocrine neoplasms.
Elvebakken H; Hjortland GO; Garresori H; Andresen PA; Janssen EAM; Vintermyr OK; Lothe IMB; Sorbye H
J Neuroendocrinol; 2023 Apr; 35(4):e13256. PubMed ID: 37017614
[TBL] [Abstract][Full Text] [Related]
5. Carboplatin in Combination with Oral or Intravenous Etoposide for Extra-Pulmonary, Poorly-Differentiated Neuroendocrine Carcinomas.
Frizziero M; Spada F; Lamarca A; Kordatou Z; Barriuso J; Nuttall C; McNamara MG; Hubner RA; Mansoor W; Manoharan P; Fazio N; Valle JW
Neuroendocrinology; 2019; 109(2):100-112. PubMed ID: 30703770
[TBL] [Abstract][Full Text] [Related]
6. European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for gastroduodenal neuroendocrine tumours (NETs) G1-G3.
Panzuto F; Ramage J; Pritchard DM; van Velthuysen MF; Schrader J; Begum N; Sundin A; Falconi M; O'Toole D
J Neuroendocrinol; 2023 Aug; 35(8):e13306. PubMed ID: 37401795
[TBL] [Abstract][Full Text] [Related]
7. Current Treatment Options in Gastroenteropancreatic Neuroendocrine Carcinoma.
Thomas KEH; Voros BA; Boudreaux JP; Thiagarajan R; Woltering EA; Ramirez RA
Oncologist; 2019 Aug; 24(8):1076-1088. PubMed ID: 30635447
[TBL] [Abstract][Full Text] [Related]
8. [Treatment of neuroendocrine tumors of the digestive tract].
Wada I; Shimizu N; Seto Y
Gan To Kagaku Ryoho; 2009 Oct; 36(10):1606-10. PubMed ID: 19838017
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors of metastatic neuroendocrine carcinoma under first-line treatment with platinum etoposide with a focus on NEC score and Rb expression: Results from the multicentre RBNEC study of the Groupe d'Etude des Tumeurs Endocrines (GTE) and the ENDOCAN-RENATEN network.
Hadoux J; Kanaan C; Durand A; Hescot S; Hautefeuille V; Cadiot G; Tauveron I; Laboureau S; Do Cao C; Walter T; Petorin C; Blanchet O; Jannin A; Gu C; Faron M; Leteurtre E; Rousselet MC; Zakeyh JJ; Marchal A; Chatelain D; Beaulaton C; Hervieu V; Ducreux M; Scoazec JY; Baudin E
Eur J Cancer; 2021 Jul; 152():100-115. PubMed ID: 34090142
[TBL] [Abstract][Full Text] [Related]
10. FOLFIRINEC: a randomized phase II trial of mFOLFIRINOX vs platinum-etoposide for metastatic neuroendocrine carcinoma of gastroenteropancreatic or unknown origin.
Hadoux J; Afchain P; Walter T; Tougeron D; Hautefeuille V; Monterymard C; Lorgis V; Thuillier F; Baudin E; Scoazec JY; Lepage C; Desgrippes R
Dig Liver Dis; 2021 Jul; 53(7):824-829. PubMed ID: 33994125
[TBL] [Abstract][Full Text] [Related]
11. European Neuroendocrine Tumour Society (ENETS) 2023 guidance paper for nonfunctioning pancreatic neuroendocrine tumours.
Kos-Kudła B; Castaño JP; Denecke T; Grande E; Kjaer A; Koumarianou A; de Mestier L; Partelli S; Perren A; Stättner S; Valle JW; Fazio N
J Neuroendocrinol; 2023 Dec; 35(12):e13343. PubMed ID: 37877341
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of Etoposide and Cisplatin vs Irinotecan and Cisplatin Therapy for Patients With Advanced Neuroendocrine Carcinoma of the Digestive System: The TOPIC-NEC Phase 3 Randomized Clinical Trial.
Morizane C; Machida N; Honma Y; Okusaka T; Boku N; Kato K; Nomura S; Hiraoka N; Sekine S; Taniguchi H; Okano N; Yamaguchi K; Sato T; Ikeda M; Mizuno N; Ozaka M; Kataoka T; Ueno M; Kitagawa Y; Terashima M; Furuse J;
JAMA Oncol; 2022 Oct; 8(10):1447-1455. PubMed ID: 35980649
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Carboplatin and Etoposide Combination Chemotherapy for Extrapulmonary Neuroendocrine Carcinoma: A Retrospective Case Series.
Imai H; Shirota H; Okita A; Komine K; Saijo K; Takahashi M; Takahashi S; Takahashi M; Shimodaira H; Ishioka C
Chemotherapy; 2016; 61(3):111-6. PubMed ID: 26636658
[TBL] [Abstract][Full Text] [Related]
14. Systemic Treatment of Gastroenteropancreatic Neuroendocrine Carcinoma.
Mollazadegan K; Welin S; Crona J
Curr Treat Options Oncol; 2021 Jun; 22(8):68. PubMed ID: 34110508
[TBL] [Abstract][Full Text] [Related]
15. [Neuroendocrine Neoplasia of the digestive tract].
Begum N; Anlauf M
Ther Umsch; 2020 Nov; 77(9):449-455. PubMed ID: 33146094
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes of locally advanced esophageal neuroendocrine carcinoma treated with chemoradiotherapy.
Honma Y; Nagashima K; Hirano H; Shoji H; Iwasa S; Takashima A; Okita N; Kato K; Boku N; Murakami N; Inaba K; Ito Y; Itami J; Kanamori J; Oguma J; Daiko H
Cancer Med; 2020 Jan; 9(2):595-604. PubMed ID: 31794158
[TBL] [Abstract][Full Text] [Related]
17. Etoposide and cisplatin versus irinotecan and cisplatin as the first-line therapy for patients with advanced, poorly differentiated gastroenteropancreatic neuroendocrine carcinoma: A randomized phase 2 study.
Zhang P; Li J; Li J; Zhang X; Zhou J; Wang X; Peng Z; Shen L; Lu M
Cancer; 2020 May; 126 Suppl 9(Suppl 9):2086-2092. PubMed ID: 32293725
[TBL] [Abstract][Full Text] [Related]
18. Randomised phase II trial of CAPTEM or FOLFIRI as SEcond-line therapy in NEuroendocrine CArcinomas and exploratory analysis of predictive role of PET/CT imaging and biological markers (SENECA trial): a study protocol.
Bongiovanni A; Liverani C; Pusceddu S; Leo S; Di Meglio G; Tamberi S; Santini D; Gelsomino F; Pucci F; Berardi R; Lolli I; Bergamo F; Ricci S; Foca F; Severi S; Ibrahim T;
BMJ Open; 2020 Jul; 10(7):e034393. PubMed ID: 32690499
[TBL] [Abstract][Full Text] [Related]
19. ENETS standardized (synoptic) reporting for neuroendocrine tumour pathology.
van Velthuysen MF; Couvelard A; Rindi G; Fazio N; Hörsch D; Nieveen van Dijkum EJ; Klöppel G; Perren A
J Neuroendocrinol; 2022 Mar; 34(3):e13100. PubMed ID: 35165954
[TBL] [Abstract][Full Text] [Related]
20. [Analysis of clinicopathological characteristics, therapeutic strategy and prognosis of 501 patients with gastric neuroendocrine neoplasms attending a single center].
Zhang BL; Lu YX; Liang WQ; Gao YH; Xi HQ; Wang XX; Zhang KC; Chen L
Zhonghua Wei Chang Wai Ke Za Zhi; 2023 May; 26(5):459-466. PubMed ID: 37217354
[No Abstract] [Full Text] [Related]
[Next] [New Search]
